Sowell Financial Services LLC Makes New $328,000 Investment in Sanofi (NASDAQ:SNY)

Sowell Financial Services LLC purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,912 shares of the company's stock, valued at approximately $328,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gradient Investments LLC boosted its stake in shares of Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after buying an additional 200 shares during the period. Providence Capital Advisors LLC grew its stake in Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after acquiring an additional 201 shares during the period. Bailard Inc. grew its stake in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after acquiring an additional 220 shares during the period. Beacon Financial Group boosted its holdings in shares of Sanofi by 1.6% in the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after purchasing an additional 222 shares during the last quarter. Finally, AdvisorNet Financial Inc boosted its holdings in shares of Sanofi by 16.4% in the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock valued at $89,000 after purchasing an additional 227 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $47.86 on Friday. The stock has a market capitalization of $117.37 billion, a PE ratio of 17.09, a P/E/G ratio of 0.98 and a beta of 0.50. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The business has a fifty day moving average price of $51.23 and a two-hundred day moving average price of $52.03. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the previous year, the company posted $1.78 EPS. The business's revenue was down 11.0% on a year-over-year basis. As a group, equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were given a dividend of $2.0369 per share. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SNY shares. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.